AZNCF - AstraZeneca's Farxiga Data And Other News: The Good Bad And Ugly Of Biopharma
AstraZeneca reports positive data for Phase III Farxiga trial
AstraZeneca (AZN) reported that Farxiga has shown robust decline in the risk of kidney failure, cardiovascular or renal death in patients suffering from chronic kidney disease. The data from the Phase III DAPA-CKD trial showed that Farxiga in combination with standard of care decreased the composite measure of worsening of renal function or risk of cardiovascular or renal death by 39% compared to placebo.
The primary endpoint of the trial was ?50% sustained decline in estimated glomerular filtration rate (eGFR), onset of end-stage kidney